Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma.
Fontanilles M, Marguet F, Beaussire L, Magne N, Pépin LF, Alexandru C, Tennevet I, Hanzen C, Langlois O, Jardin F, Laquerrière A, Sarafan-Vasseur N, Di Fiore F, Clatot F. Fontanilles M, et al. Among authors: hanzen c. Acta Neuropathol Commun. 2020 Nov 4;8(1):179. doi: 10.1186/s40478-020-01057-7. Acta Neuropathol Commun. 2020. PMID: 33148330 Free PMC article.
Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma patients.
Fontanilles M, Marguet F, Alexandru C, Langlois O, Veresezan O, Gilard V, David M, Laquerriere A, Hanzen C, Tennevet I, Di Fiore F, Clatot F. Fontanilles M, et al. Among authors: hanzen c. Support Care Cancer. 2019 Feb;27(2):477-484. doi: 10.1007/s00520-018-4336-5. Epub 2018 Jul 5. Support Care Cancer. 2019. PMID: 29978325
Deleterious impact of a generic temozolomide formulation compared with brand-name product on the kinetic of platelet concentration and survival in newly diagnosed glioblastoma.
Fontanilles M, Fontanilles A, Massy N, Rouvet J, Pereira T, Alexandru C, Hanzen C, Basuyau F, Langlois O, Clatot F, Tennevet I, Di Fiore F, Joannidès R, Lamoureux F. Fontanilles M, et al. Among authors: hanzen c. Fundam Clin Pharmacol. 2020 Aug;34(4):484-494. doi: 10.1111/fcp.12539. Epub 2020 Feb 14. Fundam Clin Pharmacol. 2020. PMID: 31994757
Impact of EGFRA289T/V mutation on relapse pattern in glioblastoma.
Noeuveglise A, Sarafan-Vasseur N, Beaussire L, Marguet F, Modzelewski R, Hanzen C, Alexandru C, Magne N, Langlois O, Di Fiore F, Clatot F, Thureau S, Fontanilles M. Noeuveglise A, et al. Among authors: hanzen c. ESMO Open. 2023 Feb;8(1):100740. doi: 10.1016/j.esmoop.2022.100740. Epub 2022 Dec 23. ESMO Open. 2023. PMID: 36566697 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 37784505
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group. de Boer SM, et al. Among authors: hanzen c. Lancet Oncol. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12. Lancet Oncol. 2018. PMID: 29449189 Free PMC article. Clinical Trial.
59 results